Skip to Content
Merck
CN
  • Nifedipine in the management of preterm labor: a systematic review and metaanalysis.

Nifedipine in the management of preterm labor: a systematic review and metaanalysis.

American journal of obstetrics and gynecology (2011-02-03)
Agustín Conde-Agudelo, Roberto Romero, Juan Pedro Kusanovic
ABSTRACT

To determine the efficacy and safety of nifedipine as a tocolytic agent in women with preterm labor. A systematic review and metaanalysis of randomized controlled trials. Twenty-six trials (2179 women) were included. Nifedipine was associated with a significant reduction in the risk of delivery within 7 days of initiation of treatment and before 34 weeks' gestation, respiratory distress syndrome, necrotizing enterocolitis, intraventricular hemorrhage, neonatal jaundice, and admission to the neonatal intensive care unit when compared with β₂-adrenergic-receptor agonists. There was no difference between nifedipine and magnesium sulfate in tocolytic efficacy. Nifedipine was associated with significantly fewer maternal adverse events than β₂-adrenergic-receptor agonists and magnesium sulfate. Maintenance nifedipine tocolysis was ineffective in prolonging gestation or improving neonatal outcomes when compared with placebo or no treatment. Nifedipine is superior to β₂-adrenergic-receptor agonists and magnesium sulfate for tocolysis in women with preterm labor.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Nifedipine, ≥98% (HPLC), powder
USP
Nifedipine, United States Pharmacopeia (USP) Reference Standard
Nifedipine, European Pharmacopoeia (EP) Reference Standard
Supelco
Nifedipine, Pharmaceutical Secondary Standard; Certified Reference Material